Please login to the form below

Not currently logged in
Email:
Password:

inotuzumab ozogamicin

This page shows the latest inotuzumab ozogamicin news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

NICE changes its mind on Pfizer’s Besponsa. England’s cost effectiveness watchdog NICE has issued a final appraisal determination recommending Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults ... We are particularly thankful to

Latest news

  • NICE to look again at Pfizer’s Besponsa after appeal NICE to look again at Pfizer’s Besponsa after appeal

    Last August, NICE turned down Besponsa (inotuzumab ozogamicin) for routine use on the National Health Service for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL) ... Pfizer is committed to ongoing

  • NICE set to reject Pfizer's leukaemia drug Besponsa NICE set to reject Pfizer's leukaemia drug Besponsa

    The National Institute of Healthcare and Excellence (NICE) is set to reject Pfizer’s orphan drug for leukaemia Besponsa (inotuzumab ozogamicin). ... David Montogomery, oncology medical director at Pfizer UK, said: “[This] frustrating decision for

  • FDA clears Pfizer's leukaemia drug Besponsa FDA clears Pfizer's leukaemia drug Besponsa

    Europe. Besponsa (inotuzumab ozogamicin), which had breakthrough status, was approved after a priority review by the FDA as this type of leukaemia is aggressive, has a very poor prognosis in adults, ... care. The rate of complete remission was

  • NICE rejects Pfizer's antibody drug for leukaemia NICE rejects Pfizer's antibody drug for leukaemia

    Evidence from clinical trial data showed no survival benefit from Besponsa (inotuzumab ozogamicin) compared to current treatment said NICE, although it noted that more people who were treated with Pfizer's ... David Montgomery, oncology medical director

  • CHMP backs two rare disease therapies at April meeting CHMP backs two rare disease therapies at April meeting

    In other news from the CHMP meeting, Pfizer picked up a positive opinion for Besponsa (inotuzumab ozogamicin) as a single-agent treatment for adults with relapsed or refractory CD22-positive

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics